JP2018536405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536405A5 JP2018536405A5 JP2018524443A JP2018524443A JP2018536405A5 JP 2018536405 A5 JP2018536405 A5 JP 2018536405A5 JP 2018524443 A JP2018524443 A JP 2018524443A JP 2018524443 A JP2018524443 A JP 2018524443A JP 2018536405 A5 JP2018536405 A5 JP 2018536405A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- polynucleotide
- linker
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562254139P | 2015-11-11 | 2015-11-11 | |
| US62/254,139 | 2015-11-11 | ||
| PCT/US2016/061668 WO2017083750A1 (en) | 2015-11-11 | 2016-11-11 | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536405A JP2018536405A (ja) | 2018-12-13 |
| JP2018536405A5 true JP2018536405A5 (enExample) | 2019-12-19 |
| JP6976244B2 JP6976244B2 (ja) | 2021-12-08 |
Family
ID=57543150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524443A Expired - Fee Related JP6976244B2 (ja) | 2015-11-11 | 2016-11-11 | 心臓状態および他の病態の処置のための複数の生物学的に活性なポリペプチドを単一のベクターから発現させるための組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11154622B2 (enExample) |
| EP (1) | EP3387010A1 (enExample) |
| JP (1) | JP6976244B2 (enExample) |
| KR (1) | KR20180069081A (enExample) |
| CN (1) | CN108713025A (enExample) |
| AU (1) | AU2016353342B2 (enExample) |
| BR (1) | BR112018009645A2 (enExample) |
| CA (1) | CA3004742A1 (enExample) |
| HK (1) | HK1259137A1 (enExample) |
| MA (1) | MA43404A (enExample) |
| MX (1) | MX2018005886A (enExample) |
| RU (1) | RU2758489C2 (enExample) |
| SG (1) | SG11201803934YA (enExample) |
| WO (1) | WO2017083750A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102673203B1 (ko) | 2016-04-20 | 2024-06-10 | 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. | Pklr의 유전자 발현 증강을 위한 조성물 및 방법 |
| CA3049652A1 (en) | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| JP7240749B2 (ja) | 2017-09-29 | 2023-03-16 | ベスファジェン・インコーポレイテッド | 心不全の予防または治療のための医薬組成物 |
| AU2018352583B2 (en) | 2017-10-16 | 2025-04-17 | Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. | Lentiviral vectors for delivery of PKLR to treat Pyruvate Kinase Deficiency |
| SG11202008539YA (en) | 2018-03-06 | 2020-10-29 | Precigen Inc | Human papillomavirus vaccines and uses of the same |
| IL277128B2 (en) | 2018-03-06 | 2025-11-01 | Precigen Inc | Hepatitis b vaccines and uses of the same |
| US12539316B2 (en) | 2018-04-11 | 2026-02-03 | Spacecraft Seven, Llc | Compositions and methods for stem cell transplant |
| IL278213B2 (en) | 2018-04-27 | 2026-04-01 | Rocket Pharmaceuticals Ltd | A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd) |
| CA3100070A1 (en) * | 2018-05-18 | 2019-11-21 | Universite Laval | Vectors for dna vaccination |
| US12528848B2 (en) * | 2018-05-25 | 2026-01-20 | The Wistar Institute Of Anatomy And Biology | Tumor-specific neoantigens and methods of using the same |
| IL280465B2 (en) | 2018-07-30 | 2025-03-01 | Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P | Methods for gene modification of hematopoietic cells |
| BR112021006182A2 (pt) | 2018-10-01 | 2021-06-29 | Adicet Bio, Inc. | composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos |
| US12698340B2 (en) | 2018-10-01 | 2026-08-04 | Adicet Therapeutics, Inc. | Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors |
| KR102985320B1 (ko) * | 2019-03-29 | 2026-07-06 | 아비오메드, 인크. | 생물학 요법 또는 벡터 유전자 요법에서 좌심실 언로딩을 위한 시스템 및 방법 |
| CN114450411A (zh) | 2019-04-01 | 2022-05-06 | 特纳亚治疗股份有限公司 | 具有工程化衣壳的腺相关病毒 |
| WO2020232527A1 (en) * | 2019-05-21 | 2020-11-26 | UNIVERSITé LAVAL | Crimean-congo hemorrhagic fever virus immunogenic compositions |
| CN114173863A (zh) * | 2019-08-07 | 2022-03-11 | 西北大学 | 用于在心脏中基因递送的材料和方法 |
| TWI897882B (zh) * | 2019-09-20 | 2025-09-21 | 英商Ｕｃｌ商業有限責任公司 | 右心室心律失常性心肌病之基因療法組合物及治療 |
| AU2021259422A1 (en) | 2020-04-20 | 2022-12-08 | Tenaya Therapeutics, Inc. | Adeno-associated virus with engineered capsid |
| WO2022032226A1 (en) * | 2020-08-07 | 2022-02-10 | Spacecraft Seven, Llc | Plakophilin-2 (pkp2) gene therapy using aav vector |
| JP7415042B2 (ja) | 2020-10-09 | 2024-01-16 | テナヤ セラピューティクス， インコーポレイテッド | プラコフィリン２遺伝子治療の方法および組成物 |
| US11781156B2 (en) * | 2020-10-09 | 2023-10-10 | Tenaya Therapeutics, Inc. | Plakophillin-2 gene therapy methods and compositions |
| MX2024001939A (es) * | 2021-08-12 | 2024-07-10 | Univ Temple | Administracion retrograda de composicion terapeutica mediante seno o vena coronarios. |
| AU2023281902A1 (en) * | 2022-06-02 | 2024-11-28 | Hugo A. Katus | S100a1 protein for use in treating and preventing infarct extension |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4985461A (en) | 1985-10-21 | 1991-01-15 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| US5117057A (en) | 1985-10-21 | 1992-05-26 | Rohm And Haas Company | Insecticidal N' substituted-N-N'-disubstituted-hydrazines |
| US5225443A (en) | 1986-05-01 | 1993-07-06 | Rohm And Haas Company | Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines |
| US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| IL100643A (en) | 1991-01-25 | 1996-10-31 | Nippon Kayaku Kk | History of hydrazine and pesticides containing these histories as an active ingredient |
| US5530028A (en) | 1992-11-23 | 1996-06-25 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| US6013836A (en) | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
| WO2001070816A2 (en) | 2000-03-22 | 2001-09-27 | Rohm And Haas Company | Ecdysone receptor-based inducible gene expression system |
| US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
| US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
| CA2438119C (en) | 2001-02-20 | 2014-12-16 | Rheogene Holdings, Inc. | Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system |
| AU2002306550B2 (en) | 2001-02-20 | 2007-10-25 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| EP1534738B1 (en) | 2001-02-20 | 2012-06-20 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| ES2385598T3 (es) | 2001-02-20 | 2012-07-27 | Intrexon Corporation | Sistema novedoso de expresión génica inducible basado en el receptor de ecdisona/receptor X retinoide de invertebrado |
| US20030027751A1 (en) * | 2001-04-10 | 2003-02-06 | Genvec, Inc. | VEGF fusion proteins |
| JP2005532781A (ja) | 2001-09-26 | 2005-11-04 | レオジーン・ホールディングス，インコーポレーテッド | ヨコバイエクジソン受容体核酸、ポリペプチド、およびそれらの使用 |
| EP1490686A2 (en) | 2001-09-26 | 2004-12-29 | RheoGene Holdings Inc. | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| US7375093B2 (en) | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
| US7304162B2 (en) | 2003-02-21 | 2007-12-04 | Intrexon Corporation | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| US9034650B2 (en) | 2005-02-02 | 2015-05-19 | Intrexon Corporation | Site-specific serine recombinases and methods of their use |
| AU2007332980A1 (en) | 2006-07-26 | 2008-06-19 | Intrexon Corporation | Methods and compositions for treating disease |
| US7719424B2 (en) | 2007-01-19 | 2010-05-18 | Igt | Table monitoring identification system, wager tagging and felt coordinate mapping |
| MX363066B (es) | 2007-05-29 | 2019-03-07 | Intrexon Corp | Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona. |
| US20090136465A1 (en) | 2007-09-28 | 2009-05-28 | Intrexon Corporation | Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof |
| JP2010539993A (ja) | 2007-10-08 | 2010-12-24 | イントレキソン コーポレーション | 遺伝子操作した樹状細胞および癌の治療のための使用 |
| US8236527B2 (en) * | 2008-03-14 | 2012-08-07 | Humanzyme Limited | Recombinant production of authentic human proteins using human cell expression systems |
| MX340972B (es) | 2008-10-08 | 2016-08-02 | Intrexon Corp | Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas. |
| CA2772610C (en) | 2009-08-28 | 2018-01-23 | The Cleveland Clinic Foundation | Sdf-1 delivery for treating ischemic tissue |
| EP2550359B1 (en) | 2010-03-23 | 2017-08-09 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
| EP2681327B1 (en) | 2011-03-04 | 2018-11-21 | Intrexon Corporation | Vectors conditionally expressing protein |
| HUE051277T2 (hu) * | 2012-11-16 | 2021-03-01 | United Biomedical Inc | Szintetikus peptiden alapuló sürgõsségi vakcina ragadós száj- és körömfájás (FMD) ellen |
| WO2014089121A2 (en) * | 2012-12-03 | 2014-06-12 | Thomas Ichim | Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases |
| WO2014145199A2 (en) | 2013-03-15 | 2014-09-18 | The Cleveland Clinic Foundation | Retrograde delivery of sdf-1 for treatment of myocardial infarction |
| WO2016187585A1 (en) | 2015-05-20 | 2016-11-24 | Viventia Bio Inc. | Deimmunized linker and methods of use |
| CN105754990A (zh) * | 2016-01-29 | 2016-07-13 | 深圳精准医疗科技有限公司 | 一种pd-1/ctla-4双特异性抗体的制备方法及其应用 |
-
2016
- 2016-11-11 WO PCT/US2016/061668 patent/WO2017083750A1/en not_active Ceased
- 2016-11-11 AU AU2016353342A patent/AU2016353342B2/en not_active Ceased
- 2016-11-11 KR KR1020187016185A patent/KR20180069081A/ko not_active Withdrawn
- 2016-11-11 JP JP2018524443A patent/JP6976244B2/ja not_active Expired - Fee Related
- 2016-11-11 MA MA043404A patent/MA43404A/fr unknown
- 2016-11-11 HK HK19101096.0A patent/HK1259137A1/zh unknown
- 2016-11-11 RU RU2018117674A patent/RU2758489C2/ru active
- 2016-11-11 EP EP16810130.1A patent/EP3387010A1/en not_active Withdrawn
- 2016-11-11 SG SG11201803934YA patent/SG11201803934YA/en unknown
- 2016-11-11 BR BR112018009645A patent/BR112018009645A2/pt not_active IP Right Cessation
- 2016-11-11 CA CA3004742A patent/CA3004742A1/en active Pending
- 2016-11-11 MX MX2018005886A patent/MX2018005886A/es unknown
- 2016-11-11 CN CN201680078586.0A patent/CN108713025A/zh active Pending
-
2018
- 2018-05-11 US US15/978,036 patent/US11154622B2/en not_active Expired - Fee Related
-
2021
- 2021-09-22 US US17/481,938 patent/US20220072159A1/en not_active Abandoned
-
2023
- 2023-10-12 US US18/485,838 patent/US20240148908A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6229038B2 (ja) | 修飾された血管作動性腸管ペプチド | |
| CN116419765A (zh) | Glp-1/gip双重激动剂、其长效缀合物，以及包括其的药物组合物 | |
| JPH11187886A (ja) | 抗−血管新生ペプチドをコードするｄｎａを含む担体：ｄｎａ複合体およびそれらの遺伝子療法における使用 | |
| JP2020172496A (ja) | 分枝状アミノ酸プローブを有するペプチド類似体 | |
| CN110229216A (zh) | 具有改善的药代动力学性质的坎普他汀类似物 | |
| JP2018536405A (ja) | 心臓状態および他の病態の処置のための複数の生物学的に活性なポリペプチドを単一のベクターから発現させるための組成物および方法 | |
| AU2002357143A1 (en) | Growth hormone releasing hormone supplementation for treating chronically ill subjects | |
| US20230390211A1 (en) | Composition for increasing expression of blood coagulation factor gene, comprising core-shell structured microparticles as active ingredient | |
| JP2024513559A5 (enExample) | ||
| US20210046148A1 (en) | Methods for Increasing the Selective Efficacy of Gene Therapy Using CAR Peptide and Heparan-Sulfate Mediated Macropinocytosis | |
| JP2024069465A5 (enExample) | ||
| IL273368B2 (en) | Composite medical preparations with increased binding capacity to albumin | |
| EP0819758A2 (en) | Cationic vehicle: DNA complexes and their use in gene therapy | |
| CN101426808A (zh) | 新颖的蛋白质转导结构域及其应用 | |
| US20080145412A1 (en) | Method of promoting angiogenesis | |
| CN100434437C (zh) | 包含异亮氨酰-缬氨酰-苏氨酰-天冬酰胺酰-苏氨酰-苏氨酸的生物活性肽 | |
| RU2377249C2 (ru) | Биологически активные производные пептида vapeehptllteaplnpk | |
| WO2018144817A1 (en) | Modified cxcl12 polypeptides and uses thereof | |
| WO2025092001A1 (zh) | 抗血小板聚集多肽或其活性片段、制备方法及应用 | |
| CN118843639A (zh) | Gipr和glp2r的肽双重激动剂 | |
| US20040110696A1 (en) | Gene therapy system and method using alpha-msh and its derivatives | |
| JP2004509065A (ja) | α−ＭＳＨおよびその誘導体を用いる遺伝子治療システムおよび方法 | |
| HK40002026A (en) | Fusion proteins with extended serum half life | |
| HK1126790B (en) | Biologically active peptide vapeehptllteaplnpk derivatives |